Oncology Billing Services / Part B Drug Wastage

Two modifiers. One vial. Very different consequences.

On any separately payable single-use vial drug you give a Medicare Part B patient, CMS wants one of two modifiers on the claim. JW says you discarded part of the vial. JZ says you discarded nothing. Put the wrong one on, or leave both off, and a clean oncology claim becomes an audit finding.

Short answer: JW reports and bills the discarded amount from a single-use vial. JZ attests zero waste. Both are mandatory. The pair is the compliance signal, not an option.

The side-by-side matrix

Same drug, same NDC, same ASP-based rate. What changes is whether any product went in the sharps bin and whether your documentation can prove it. Here is the head-to-head.

Modifier JW

Drug amount discarded / not administered

When it applies

A single-use vial or single-use package where the full contents were not administered and the remainder was discarded.

How it is billed

Two lines for the same HCPCS. One line for units given, one line with JW for the wasted units. Both units are payable.

Payment effect

The discarded units are reimbursed at the Part B ASP rate, so the practice is made whole for product it could not reuse.

Documentation

Medical record must show the amount administered and the amount discarded. The waste has to reconcile to vial size and dose.

Common trap

Appending JW to a multi-dose vial, or billing waste on a drug that has no single-use presentation.

Modifier JZ

Zero drug amount discarded / not administered

When it applies

A single-use vial or package where the entire billable amount was administered and nothing was discarded.

How it is billed

One line for the HCPCS with JZ appended. It is an attestation of zero waste, not a second payable line.

Payment effect

No extra units are paid. JZ carries no dollars. Its job is to close the compliance loop and stop a denial.

Documentation

Record supports that the dose equaled the vial and no remainder was left. The absence of waste is itself the fact.

Common trap

Omitting JZ entirely because the line has no waste, which is exactly what CMS edits look for.

Four scenarios oncology teams actually see

The rule reads simple. The infusion suite is not. These are the everyday combinations that decide whether the claim pays or bounces.

Pays clean

Single-use vial, partial dose, waste discarded

Dose is 380 mg from a 440 mg single-use vial. Bill administered units on line one, the 60 mg remainder with JW on line two. Both lines pay at ASP. Waste is documented and reconciled.

Pays clean

Single-use vial, full dose, no waste

The ordered dose consumes the entire vial. One line, JZ appended. No waste units, no second line. The attestation clears the wastage edit and the claim moves.

Audit exposure

Waste billed with no modifier

Discarded product billed as extra units with neither JW nor JZ. The line looks like overbilling to CMS edits and to a post-pay reviewer. This is the classic drug-wastage takeback.

Denial risk

JW on a multi-dose vial

JW appended to a drug supplied only in multi-dose form. Multi-dose vials are not eligible for discarded-drug payment, so the waste units are denied and the pattern draws scrutiny.

How ASP pricing turns the modifier into money

Under Part B, most of these drugs are paid on the Average Sales Price methodology. The modifier decides how many units flow into that formula, and whether the waste units get their own payable line.

Vial opened

Single-use presentation, dose drawn for the patient.

Waste decided

Remainder discarded, or the full vial used with none left.

Modifier set

JW on the discarded units, or JZ on the fully used line.

ASP applied

Payable units priced on the CY2026 ASP rate for that HCPCS.

Claim clears

Edits satisfied, no wastage flag, no manual review hold.

The 2026 guidance this rests on

None of this is folklore. It is written into the current rules by name. Cite these when a payer pushes back.

CMS CY2026 OPPS Final Rule governs how hospital outpatient oncology departments report and are paid for separately payable drugs, including the discarded-drug policy for single-use vials.
CMS CY2026 PFS Final Rule sets the physician fee schedule framework for drugs furnished incident to care in the office and clinic setting, where most infusion practices bill.
JW and JZ drug-wastage modifiers are the required reporting pair for discarded amounts from single-use vials and single-use packages under CMS policy.
Part B ASP pricing methodology is the basis for reimbursing both the administered and the JW-billed discarded units for separately payable drugs.
Radiation oncology coding under the CPT 77xxx radiation treatment series and HCPCS radiopharmaceutical codes intersects with wastage rules whenever a single-use radiopharmaceutical is only partially used.

Why the pair is worth getting right

Wastage on high-cost oncology drugs is not a rounding error. A single vial can carry four figures of product, and the discarded portion is often legitimately payable. Miss JW and you leave that money on the table. Miss JZ and you invite a denial or a post-pay review on a line that was perfectly correct.

2Modifiers, both mandatory

1Vial per decision point

≥95%ASP-RCM coding accuracy standard

Clean wastage capture, every vial, every claim

ASP-RCM builds the JW and JZ logic into your oncology billing at the point of charge capture, reconciles waste to vial size, and holds our coding accuracy at 95% or higher so the discarded-drug dollars land and the zero-waste lines clear. No leaked revenue, no wastage takebacks.

Talk to our oncology billing team